Skip to main content

Walder Award

The Martin E. and Gertrude G. Walder Award for Research Excellence is given annually to a faculty member in any school or discipline within the University, in recognition of excellence in research.

The award was established by Dr. Joseph A. Walder, who earned his doctorate and medical degrees at Northwestern, then founded a company which supplies synthetic DNA for research and clinical applications.

Each year the Provost identifies a broad academic field as the area from which nominations are solicited from school deans. The award carries a stipend of $15,000.

Congratulations to the 2016 Recipient

Ali Shilatifard

Ali Shilatifard

Robert Francis Furchgott Professor and Chair, Biochemistry and Molecular Genetics, Feinberg School of Medicine

Dr. Ali Shilatifard is a biochemist and molecular biologist and a respected expert in the field of transcription and epigenetics, specifically as it relates to cancer biology. He has an immense interest in understanding the intricate molecular mechanisms of the regulation of gene expression, the mechanisms that activate or suppress a particular gene’s trait, especially how both inherited and environmental factors, or epigenetics, play a role in the development of human disease, including cancer.

As a Jane Coffin Childs postdoctoral fellow, Shilatifard made a seminal contribution to the field of leukemia biology by identifying the first function of any of the MLL translocation partners, which is when a section of one chromosome changes place with that of another chromosome, creating a mutation. For the 20 years that followed, he has dedicated his career to pursuing these important questions that directly relate to improving outcomes in individuals’ prognoses when diagnosed with cancer. 

Shilatifard’s studies have made significant inroads to understanding the cause of childhood leukemia. Research from his laboratory is leading to the development of promising, target-specific drugs for childhood leukemia and other forms of cancers. The epigenetic inhibitors developed in Shilatifard’s laboratory are being tested for the treatment of childhood leukemia, brain cancer and other solid tumors.

Shilatifard has been recognized by the Leukemia and Lymphoma Society, as the recipient of the Sword of the American Cancer Society, and received the AMGEN Award from the American Society of Biochemistry and Molecular Biology.  He has been funded through three major grants from the National Institutes of Health and the National Cancer Institute.

Recently, Shilatifard was selected as an inaugural recipient of the Outstanding Investigator Award from the National Cancer Institute. He serves as a senior editor for the journal Science, a deputy editor for Science Advances, editor for Molecular and Cellular Biology, and also serves on the scientific advisory boards of Genentech, the Max Planck Society, and Cell Signaling Technology.

Back to top